This study was conducted to determine the risk of menopause and infertility in female childhood cancer survivors who received abdominal-pelvic radiation and/or chemotherapy with alkylating agents in comparison with those who were treated by nonsterilizing surgery only. Females who were diagnosed in 1964-1988 before age 20 years with a histologically confirmed malignancy and who had survived for at least 5 years, had attained age 18, and were alive at time of study were identified through the Ontario Cancer Registry. Reproductive outcomes were ascertained by a telephone-administered questionnaire, and treatment data were abstracted from medical records for 830 subjects aged 18-49 years; 719 survivors who were nonmenopausal at the end of treatment were included in the analyses. Survivors who received both alkylating agents and abdominal-pelvic radiation were more likely to be postmenopausal than were those who underwent surgery (risk ratio = 2.58; 95% confidence interval: 1.14, 5.80). Women treated with abdominal-pelvic radiation alone had a fertility deficit of 23% compared with those in the surgery group; the deficit was restricted to women diagnosed postpuberty. Risks of menopause and infertility increased with increasing dose of abdominal-pelvic radiation and amount of alkylating agent. Am J Epidemiol 1999; 150:245-54.
Although cancer has become a curable disease for many children, concerns remain about late complications of therapy (1) . The initial adverse responses of the ovary to ionizing radiation are ovarian failure (2-4), germ cell destruction (5) , and amenorrhea (2, 6, 7). These effects vary by age, dose, and site of treatment. Ovarian failure has also been associated with chemotherapy, with toxicity being related to dose (8, 9) , age (8, (10) (11) (12) (13) , and type of chemotherapeutic agent (9, 14) . A multicenter National Cancer Institute retrospective cohort study estimated the overall fertility of female survivors of childhood cancer to be 7 percent less than that of their sibling controls. These women were more affected by radiation below the diaphragm than by chemotherapy with alkylating agents or surgery only (15) . Further analyses of the National Cancer Institute cohort indicated a considerable risk of early menopause among those survivors treated with radiation below the diaphragm in combination with alkylating agents (16) .
Studies of reproductive outcomes after treatment for childhood cancer have included primarily women treated prior to the mid-1970s. We therefore conducted a study of recently treated female childhood cancer survivors so that the effects of more current therapeutic regimens could be examined. The goal of this retrospective cohort study of women was to determine whether there is an increased risk of menopause or infertility in those female survivors of childhood cancer who received chemotherapy with alkylating agents and/or abdominal-pelvic radiation compared with those who received nonsterilizing surgery.
MATERIALS AND METHODS

Identification of subjects
This study employed a retrospective cohort design using the Ontario Cancer Registry to identify a cohort of female childhood cancer survivors. Females who met the following criteria were eligible: diagnosed with any histologically confirmed malignancy before age 20 years; diagnosed with a first primary cancer between 1964 and 1988; resident of Ontario at the time of diagnosis; survived for at least 5 years after diagnosis; at least 18 years of age at the study start date; and still alive. There were 1,581 women who met the study criteria.
Data collection
Each woman's physician was requested to provide consent for us to invite her to participate in the study, as well as her current name and address, her state of knowledge regarding her cancer diagnosis, and whether she had had a second primary cancer diagnosis. After physician consent was secured, subjects were sent an introductory letter, the questionnaire, and a consent form for access to cancer treatment data. The questionnaire focused on the subject's pregnancy history with additional questions on demographic details, menstrual and fertility histories, and oral contraceptive and hormone use. Information was recorded by telephone by specially trained interviewers between November 1993 and December 1994.
Menopausal status was determined from responses to the questions, "Have you stopped having periods?" and "Have you ever used hormonal supplement pills?" Infertility was assessed by responses to the following three questions: "Have you ever tried for one year or more to become pregnant and been unable to?"; "Have you ever been told you had a fertility problem?"; and "How many times have you been pregnant?"
Cancer therapy data were abstracted onto a specially prepared form from cancer treatment center and hospital records. Information collected included the type and dates of therapy, the site of surgery, the dose of radiation, and the name of the chemotherapeutic agent. Subjects were then classified into one of five mutually exclusive treatment groups (nonsterilizing surgery, chemotherapy with alkylating agents, abdominalpelvic radiation, alkylating agents plus abdominalpelvic radiation, and all other treatments). The nonsterilizing surgery group, which was the comparison group, included subjects who either had had no treatment or had received only surgery. Those who received sterilizing surgery were excluded from the analysis. Those who received chemotherapy with any of the following drugs-busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lorhustine, mechlorethamine, melphalan, or procarbazine-were considered as having chemotherapy with alkylating agents. Subjects who received any radiation treatment to the pelvis, abdomen, lumbar and/or sacral spine, hip joint or femur or who had had whole-body radiation were defined as having abdominal-pelvic radiation. The "other treatment" group comprised subjects who received chemotherapy without alkylating agents and/or radiation above or below the abdomen. Only treatment that occurred prior to menopause, before a second primary cancer, or within 5 years after diagnosis was included.
Statistical methods
Descriptive analyses were done using the computer program SAS (17) . The associations between menopause or infertility and type of cancer treatment were assessed by estimating the risk ratios and odds ratios and their 95 percent confidence intervals with the EGRET statistical software package (18) or SAS (17) .
The risk ratio estimates for menopause were calculated by using a Cox's proportional hazards regression model, stratified according to two age-at-end-of-followup groups (^30 and >30). Tune to event was calculated from the age at which a woman started menstruating or age at end of treatment, whichever came later, to age at menopause or end of follow-up. Age at end of follow-up was one of the following: age at second primary cancer, age at relapse (after 5 years postdiagnosis), or age at interview (whichever occurred first).
A Cox proportional hazards regression model was also used to model the time to first pregnancy of women in the specific treatment groups of interest relative to women receiving surgery (relative fertility). Since age at marriage was unknown and marriage rates did not differ between the treatment groups, time of follow-up (i.e., time at risk of pregnancy) was calculated from age at menstruation or age at end of treatment, whichever came later, to age at first pregnancy or end of follow-up (as described above). The analysis of time to first pregnancy was conducted controlling for marital status and age at end of follow-up. Data were censored on age at menopause to account for differences in risk and age at menopause between treatment groups. Odds ratio estimates for the other two measures of infertility (i.e., report of difficulty becoming pregnant and report of the subject having been told that she had a fertility problem) were estimated by using unconditional logistic regression, adjusted by age at interview.
To assess the effect of dose of radiation to the pelvis or abdomen, subjects who had received abdominalpelvic radiation were divided into three subgroups. The low-dose group comprised subjects who had received less than 2,000 centigray (cGy) (as other studies have shown that about 2,000 cGy are required to cause gonadal impairment and sterility in young girls), the medium-dose group comprised subjects who received between 2,000 and 3,500 cGy, and the highdose group comprised subjects who received more than 3,500 cGy (19) .
To summarize subjects' exposure to chemotherapy with alkylating agents, an alkylating-agent score was developed based on the number of alkylating agents received by each patient and the number of months each drug was taken (20) . Each alkylating-agent month Menopause and Infertility after Childhood Cancer 247 of use was given a score of one. All of the scores corresponding to the patient's treatment course were added together and rounded to the nearest integer. Subjects with scores up to the 50th percentile were considered to be in the low-dose group (scores of 1-13), those with scores between the 50th and 75th percentiles were considered to be in the medium-dose group (scores of [14] [15] [16] [17] [18] [19] [20] [21] , and those with scores above the 75th percentile (>21) were considered to be in the high-dose group.
The effect of timing of treatment in relation to onset of puberty was examined by an analysis stratified on diagnosis before or after onset of menstruation. 
RESULTS
Consent and contact information was provided by physicians for 1,108 of the 1,581 female childhood cancer survivors who met the study criteria (table 1) . Of the 1,108 subjects with physician consent, 864 (78.0 percent) were interviewed, although only 830 had treatment information abstracted. The majority of the nonparticipating women (n = 154) were not interviewed because we were unable to identify a current address or telephone number for them. After further exclusion of women who had sterilizing surgery (n = 27), had a second primary cancer before starting to menstruate (n = 4), had never had a menstrual period (n = 28), became menopausal before (n = 4) or during (n = 17) treatment, or were of unknown menopausal status at the end of treatment (n = 31) (since they had been on birth control pills from time of diagnosis to interview), 719 subjects remained for analysis.
The treatment groups differed by type of cancer (table 2) . Subjects who received chemotherapy with alkylating agents either alone or in combination with abdominal-pelvic radiation were more often diagnosed with tumors that occur in children over age 10 years, namely, lymphomas and bone tumors. Subjects who received abdominal-pelvic radiation were more likely to be diagnosed with tumors that occur in children under age 4 years, namely, renal tumors (24.0 percent) and central nervous system tumors (17.5 percent). Those in the surgery group were most often diagnosed with epithelial neoplasms (53.7 percent).
The essentially all-White survivors were between ages 18 and 49 years at the time of interview, with a median age of 28. The treatment groups differed sig- (table 3) .
Survivors who received chemotherapy with alkylating agents were more likely to have been diagnosed after 1980 and, consequently, were younger at interview and had the fewest years of follow-up. In contrast, survivors who received abdominal-pelvic radiation were younger at diagnosis and more likely to have been diagnosed prior to 1975 and therefore had the most years of follow-up. Subjects who received both chemotherapy with alkylating agents and abdominalpelvic radiation were intermediate to those who received eimer of these treatments alone. These results reflect the predominant diagnostic groups in these treatment groups and criteria for entry into the cohort.
Sixty-three women (8.8 percent) had become menopausal since completing their cancer therapy at a median age of 24 years; 29 of these (46 percent) had had a surgical menopause. A significantly elevated risk of menopause was seen in women who received both abdominal-pelvic radiation and chemotherapy with alkylating agents (risk ratio (RR) = 2.58, 95 percent confidence interval (CI): 1.14, 5.80) compared with the surgery group (table 4). For women who received abdominal-pelvic radiation only, the risk was elevated, but not significantly so. There was no increase in risk for women treated with chemotherapy with alkylating agents alone or with other treatments.
Women diagnosed before puberty had a nonsignificant increased risk of menopause when treated with abdominal-pelvic radiation alone or in conjunction with alkylating agents (table 4). Women diagnosed after puberty had a significantly elevated risk of menopause when treated with abdominal-pelvic radiation plus alkylating agents compared with the surgery group (RR = 3.23, 95 percent CI: 1.33, 7.82), although this risk ratio estimate was not significantly different from that for those diagnosed before puberty.
The risk of surgical menopause did not differ from that in the comparison group for any treatment group, except other treatments (RR = 0.30, 95 percent CI: 0.09, 0.98) (results not shown). However, for nonsurgical menopause, women treated with alkylating Of the 368 women who reported having been married (or living as married) and who were still menstruating after age 18 years, 57 (15.5 percent) stated that they had had difficulty becoming pregnant after trying for 1 year or more. Women treated with abdominalpelvic radiation had greater than a twofold increased risk of having difficulty becoming pregnant relative to the surgery group (table 6) .
Because the group of survivors in this study comprised predominantly young women, the true fertility status of many may be unknown because they have not yet tried to become pregnant. Therefore, infertility was also examined by whether a subject had ever been told by a physician that she had a fertility problem (note that this need not imply a diagnosed problem, but could be speculation only). Of the 719 subjects, 131 (18.2 percent) had been told they had or might have a fertility problem and/or were on medication to increase fertility. Women treated with both alkylating agents and abdominal-pelvic radiation had a ninefold increase in risk, while those who received either one of these treatments had lower, but significant, risk ratios (table  6) .
Treatment with abdominal-pelvic radiation was associated with a nonsignificant fertility deficit of 23 * Seventy-one subjects had both abdominal-pelvic radiation and chemotherapy with alkylating agents and are included in both treatment groups.
t No., number of subjects in the treatment subgroup who had experienced menopause. X RR, risk ratio; Cl, confidence interval; Abd-pelvic rad, abdominal pelvic radiation. § Alkylating agent score denotes the cumulative number of alkylating agent-months. • Includes married or lived as married subjects only; time period for trying to become pregnant was 1 year or more.
t No., number of subjects in the treatment subgroup who had experienced infertility. i OR, odds ratio; Cl, confidence interval; CT with AA, chemotherapy with alkylatJng agents; Abd-pelvic rad, abdominal pelvic radiation.
§ Indicates nonsterilizing surgery.
percent (table 7) . There was no apparent effect of alkylating agents administered alone or in combination with abdominal-pelvic radiation or other treatments. Women diagnosed before puberty did not have a fertility deficit when treated with abdominal-pelvic radiation and/or alkylating agents compared with the surgery group (table 7) . In fact, women treated with both abdominal-pelvic radiation and alkylating agents had about a twofold increased chance of becoming pregnant. Women diagnosed after puberty had a 16 percent fertility deficit when treated with abdominalpelvic radiation alone and had no fertility deficit when treated with alkylating agents alone or in conjunction with abdominal-pelvic radiation compared with the surgery group. For women who received abdominalpelvic radiation alone, age at diagnosis (before vs. after puberty) may modify the relation between fertility and treatment.
There was evidence that the fertility deficit rises significantly with increasing dose of abdominal-pelvic radiation (test for trend, % 2 = 5.75, p = 0.017) (table 8) .
Women treated with 2,000-3,499 cGy had a fertility deficit of 22 percent, and those in the highest dose group (>3,5OO cGy) had a 32 percent fertility deficit. The fertility deficit also rose significantly with increasing alkylating-agent score (test for trend, x 2 = 6.73, p = 0.009). Women with alkylating-agent scores of 1-13 or 14-21 had no fertility deficit, while those with scores of greater than 21 had a fertility deficit of 22 percent.
DISCUSSION
The primary objectives of this study were to determine whether female childhood cancer survivors treated with chemotherapy with alkylating agents and/or abdominal-pelvic radiation were at an increased risk of menopause or infertility compared with those treated with surgery. Results indicated that survivors who received both chemotherapy with alkylating agents and abdominal-pelvic radiation were more likely to be postmenopausal than were those who received surgery alone. Our analysis found that the risk Nonsterilizing surgery (n = 162)
Abd-pelvic radf-(cGy)(n = 225) <2,000 2,000-3,499 £3,500
Alkylating agent score (n = 220) § • Relative fertility indicates the rate of first pregnancy in the survivors compared with the nonsterilizing surgery group, after adjustment for marital status and age at follow-up, censoring on age at menopause. Seventy-one subjects had both abdominal-pelvic radiation and chemotherapy with alkylating agents.
t No., number of subjects in the treatment subgroup who were ever pregnant. % Cl, confidence interval; Abd-pelvic rad, abdominal pelvic radiation. § Alkylating agent score denotes the cumulative number of alkylating agent-months.
of surgical menopause did not differ between the treatment groups of interest, although the risk of nonsurgical menopause did. Women who received abdominalpelvic radiation may be at an increased risk of being infertile, measured as "having tried unsuccessfully to become pregnant for more than one year" or as relative fertility. Fertility deficits were slightly, although not significantly, greater in women diagnosed after puberty than in those diagnosed before puberty. There was evidence that the risks of menopause and infertility increased with increasing amount of abdominalpelvic radiation and/or alkylating agents received. The only other study that examined the risk of early menopause after treatment for childhood cancer of which we are aware was the National Cancer Institute study (16) . This study also found a significantly increased risk of early menopause among those survivors diagnosed with cancer between ages 13 and 19 years and treated with radiation below the diaphragm in combination with alkylating agents compared with sibling controls (21) . In general, the results of the National Cancer Institute study are similar to those from our study, although the two studies do comprise females treated during different time periods. Females in the National Cancer Institute cohort were diagnosed prior to 1975, were treated primarily with radiotherapy or surgery, and were most likely not exposed to multiagent chemotherapy. In contrast, the majority (65.0 percent) of females in our study were diagnosed after 1975 and were probably treated with more aggressive and multiagent chemotherapy. Although it was assumed that women treated with alkylating agents alone in our study may have had an increased risk of menopause, this was not observed (RR = 0.77, 95 percent CI: 0.30, 1.97).
In terms of infertility, data on a subsample of the National Cancer Institute cohort found no significant differences between survivors and sibling controls according to two criteria: unsuccessful attempts for a year or more to become pregnant, and a definite diagnosis of a fertility problem (22) . However, these results are for male and female survivors combined and do not examine the risk for the different treatment groups as was effected in our study. As in our study, the survivors in the National Cancer Institute study were more likely to have been advised by a physician to avoid a pregnancy, especially if they had been treated with combined radiation and chemotherapy.
When relative fertility was examined in the National Cancer Institute cohort study (15) , it was found that the women were more affected by radiation below the diaphragm (relative fertility, 0.78) than by alkylating agents (relative fertility, 1.02); these results are very similar to ours (relative fertility, 0.77 for abdominalpelvic radiation and 1.06 for alkylating agents).
When our analysis was repeated excluding subjects diagnosed with specific tumors (i.e., central nervous system tumors or gonadal and germ cell tumors), which may themselves induce menopause or infertility (due to the effects of the tumor on behavioral patterns (23) or structural damage to reproductive organs or germ cells), results remained unchanged, suggesting that observed effects are probably related to treatment.
In this study, we found that the increased risk of menopause and decreased relative fertility were confined to those treated after puberty. For those who received radiotherapy, the size of the dose required to produce gonadal impairment was related to age at treatment, which relates to the number of oocytes preAm J Epidemiol Vol. 150, No. 3, 1999 sent (19) . For those who received chemotherapy, prepubertal ovaries, not yet under cyclic hormonal control (24) (25) (26) , may be more resistant than postpubertal gonads to damage by alkylating agents (8, 27) . Aside from the biological explanation that prepubertal ovaries not under cyclical control may be more resistant to antitumor therapy, another possible explanation for the reduced risk of menopause or infertility in women diagnosed prior to puberty could be selection bias in relation to criteria for eligibility for the study and this analysis (16) : Women diagnosed before puberty had to have reached age 18 years to be in the study cohort and still be menstruating at the end of treatment to be included in the analysis. Our data suggest that treatment before puberty does affect ovarian function: Subjects who were treated prepubertally and who never had a menstrual period were more likely to have received abdominal-pelvic radiation and/or chemotherapy with alkylating agents (78.8 percent) than were those treated prepubertally who did subsequently menstruate (27.7 percent).
For girls and young women, a total dose of about 2,000 cGy is required to produce gonadal impairment and sterility (19) . The site of radiotherapy is also important, with a higher percentage of women experiencing ovarian failure if they received whole-abdominal radiation (2, 4) , scatter dose to their abdomen from spinal radiation (28, 29) , or total-body radiation (30) . In our study, there was evidence that the risks of menopause and infertility increased significantly with increasing dose of abdominal-pelvic radiation.
The effects of chemotherapy on female ovarian failure are also dose dependent (8, 9, 31) . The nature of the chemotherapy is also significant, with alkylating agents most commonly associated with persistent infertility (31, 32) . The risks of menopause and infertility increased significantly by alkylating-agent score.
The validity of our results depends largely on the participation rate of the cohort, the selection of the comparison group, and methods of data collection. This study retrospectively identified a cohort from a population-based cancer registry within a health care system that has maintained adequate records of exposure (i.e., treatment) dating back to the start of the study. Selection bias can occur in retrospective cohort studies if subjects remaining in the study differ from those lost to follow-up with respect to exposure status and/or disease occurrence (33) . Participating and nonparticipating subjects did differ in our study by year of diagnosis and by diagnostic group. Nonparticipating subjects are more likely to have been diagnosed between 1964 and 1974 (39.7 vs. 33 percent of participants) and, consequently, would have been slightly older at the start of the study (with 37.9 percent of the nonparticipants being over age 30 years vs. 31.7 percent of participants) and would have had a greater number of years of follow-up (with 55.9 percent having survived 16 years or more postdiagnosis vs. 47.7 percent of participants). In addition, the nonparticipants were diagnosed most often with epithelial neoplasms (26.1 vs. 16.4 percent of participants) and central nervous system tumors (21.3 vs. 12.1 percent of participants). Additional follow-up of nonparticipants diagnosed prior to 1975 would probably not have significantly altered our results, since similar findings have arisen from previous studies of survivors diagnosed primarily prior to 1975 (15, 16) . Additional follow-up of nonparticipants diagnosed with central nervous system tumors would also not have significantly changed our results, since our own analysis in which subjects diagnosed with these tumors were excluded gave results similar to the main analysis. However, inclusion of these subjects as well as nonparticipants diagnosed with epithelial neoplasms would have contributed additional reproductive events and enhanced precision of estimates. Nevertheless, the numbers of women in this analysis are comparable with those in the National Cancer Institute cohort and the British cohort of female survivors, and our study has the largest number of more recently treated women (i.e., 65.9 percent treated after 1975).
Female survivors who appeared to meet all of the study criteria but were not alive at the start of the study were excluded from participating, as proxy respondents were not incorporated into this study. The number of eligible women who died before the start of the study is unknown. However, it is likely that these women would have been similar to the nonparticipants in that they would have been diagnosed prior to 1975 and older at the start of the study. As previously mentioned, inclusion of these women would not be expected to significantly alter our results. In addition, findings similar to ours have been reported in previous studies of childhood cancer survivors that did include proxy respondents (15, 16) .
The use of a referent group of women who received only surgery seems appropriate in our study because in the National Cancer Institute study the surgery-only group did not have an increased risk of menopause or infertility when compared with their sibling controls (15, 16) . Using an internal control group can help to separate the effects on reproductive outcomes of treatment from those of having cancer. It has been shown in this and one other study (22) that women who have cancer may be more likely to be told by their physician that they might have a fertility problem and therefore might not try to become pregnant. In addition, the choice of an internal control group may separate the effects of treatment from any association that may exist between infertility and a possible genetic disposition to childhood cancer. However, surgically treated cancers have less ability to metastasize and may represent a type of genetic background different from those cancers requiring chemotherapy and/or radiotherapy.
Reproductive outcomes were ascertained from respondent's recall of events through a telephoneadministered questionnaire. Information on menopause or infertility could also have been obtained from the subject's medical chart. However, the assumption that medical records are more "objective" and accurate than are self-reports has not always been supported. For example, a recent study showed that different criteria appear to have been used within different hospitals for recording past reproductive events, and possible omissions and errors were found in recording certain procedures and medications prescribed (34) . Medical records would also have been unavailable for some subjects in Ontario, since hospital records can be destroyed after 10 years from last visit. Previous studies have shown that women recall with acceptable accuracy age at menarche, age at menopause, oral contraceptive use, and number of prior pregnancies (35) .
The results of this study are broadly similar to those reported in the literature for early menopause and infertility in female survivors of childhood cancers. They suggest that the increased risks observed in previous studies of female survivors treated prior to 1975 have not changed for those treated after 1975. After therapy ends, patients should be informed about their future fertility. A female survivor of childhood cancer who receives both abdominal-pelvic radiation and chemotherapy with alkylating agents may have a smaller window of fertility as a result of her risk of early menopause. In addition, women who receive abdominal-pelvic radiation have slightly reduced fertility.
